PLA2G4D: A Potential Drug Target (G283748)

Target Name: PLA2G4D

NCBI ID: G283748

PLA2G4D

PLA2G4D: A Potential Drug Target

PLA2G4D, also known as phospholipase A2 group IVD, is a protein that is expressed in various tissues throughout the body. It is a key enzyme in the phosphatidyl choline (PA) cycle, a critical pathway for the synthesis of cell membranes. This cycle is vital for maintaining the structural integrity and function of cells, and it is also involved in the regulation of various cellular processes.

One of the unique features of PLA2G4D is its ability to catalyze the breakdown of phospholipid esters, which are the major structural components of cell membranes. This process is essential for the formation of new phospholipid esters, which are then involved in the synthesis of the next step in the PA cycle, phosphorylcholine (PC).

The ability of PLA2G4D to catalyze the breakdown of phospholipid esters makes it an attractive drug target. Many diseases are caused by the dysfunction of cell membranes, and the ability of PLA2G4D to regulate these processes makes it a potential therapeutic target.

One of the key advantages of PLA2G4D as a drug target is its high expression level in various tissues. It is expressed in the brain, heart, liver, and pancreas, among other tissues, and its levels are typically higher than those of other proteins. This makes it an attractive target for drug development because it is easier to achieve high levels of the drug in the target tissues.

Another advantage of PLA2G4D is its involvement in various cellular processes. It is involved in the regulation of cellular signaling pathways, including the TGF-β pathway. This pathway is involved in the regulation of cell growth, differentiation, and survival, and it is a key factor in the development and progression of many diseases.

PLA2G4D is also involved in the regulation of inflammation. It is a potent inhibitor of the expression of pro-inflammatory cytokines, such as TNF-伪 and IL-1尾. This makes it an attractive target for the treatment of inflammatory diseases.

In addition to its involvement in cellular signaling pathways and inflammation, PLA2G4D is also involved in the regulation of cell signaling pathways that are critical for the development and progression of cancer. It is a potent inhibitor of the inhibitor of apoptosis (IAP), a protein that is involved in the regulation of cell death.

PLA2G4D is also involved in the regulation of the production of various signaling molecules, including neurotransmitters and hormones. This makes it an attractive target for the treatment of neurodegenerative diseases.

In conclusion, PLA2G4D is an attractive drug target due to its high expression level in various tissues, its involvement in various cellular processes, its ability to regulate inflammation, and its involvement in the regulation of cell signaling pathways that are critical for the development and progression of cancer. Further research is needed to fully understand the role of PLA2G4D in these processes and to develop effective treatments.

Protein Name: Phospholipase A2 Group IVD

Functions: Calcium-dependent phospholipase A2 that selectively hydrolyzes glycerophospholipids in the sn-2 position (PubMed:14709560). Has a preference for linoleic acid at the sn-2 position (PubMed:14709560)

The "PLA2G4D Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PLA2G4D comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets